MingMed Biotechnology is a clinical stage company dedicated to developing First-in-Class pharmaceutical products. It has already made world-class breakthroughs in developing novel therapies in the fields of ophthalmology, recombinant BoNT, immune-oncology, gene editing-based immunotherapy and pet medicine. There are currently over 10 products in its R&D pipeline, most of which are First-in-Class medications for unmet medical needs and are at clinical stage. MingMed is committed to develop innovative medicines targeting the true causes of diseases.
Location: China, Guangdong Province, Guangzhou City
Employees: 201-500
Founded date: 2019
Investors 2
| Date | Name | Website |
| 05.02.2022 | Lightspeed... | lsvp.com |
| - | Lightspeed... | lightspeed... |
Mentions in press and media 3
| Date | Title | Description | Source |
| 06.01.2022 | MingMed to Present at the 40th Annual J.P. Morgan Healthcare... | GUANGZHOU, China, Jan. 6, 2022 /PRNewswire/ -- MingMed Biotechnology, a clinical stage company dedic... | en.prnasia... |
| 02.12.2021 | MingMed Biotechnology Announces U.S. FDA Approval for IND Ap... | GUANGZHOU, China, Dec. 2, 2021 /PRNewswire/ -- MingMed Biotechnology, a clinical stage company dedic... | marketscre... |
| 02.12.2021 | MingMed Biotechnology Announces U.S. FDA Approval for IND Ap... | GUANGZHOU, China, Dec. 2, 2021 /PRNewswire/ -- MingMed Biotechnology, a clinical stage company dedic... | en.prnasia... |